Memphasys Ltd (AU:MEM) has released an update.
Memphasys Ltd, a reproductive biotechnology firm, is experiencing accelerating sales in Japan for its advanced Felix™ System, used in assisted reproductive technology, with expectations of sales recognition in Q4FY24. The company has also initiated exclusive distribution in Canada and New Zealand, and is progressing with regulatory updates and new product development, including the RoXsta diagnostic device for oxidative stress load, potentially applicable in various industries.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.
